Biden's Prostate Cancer Diagnosis Raises Questions About Late Detection and Transparency

Strategic Insights -

As the 82-year-old Joe Biden makes history as the oldest person to assume the presidency, questions are being raised about his clear decline in health. Recently, it has come to light that he has been diagnosed with a stage four prostate cancer that has spread to his bones. According to medical specialists, the cancer cells have a disordered appearance with a Gleason score of nine out of 10, which means that the cancer is aggressive and can only be controlled, not cured. The late detection of Biden's cancer has raised concerns about the level of medical care he received during his presidency and whether his team deliberately failed to screen him for the disease.

Key Takeaways:

  • Biden's prostate cancer was reportedly detected at stage four, with the cancer having spread to his bones.
  • The Gleason score of the cancer cells is nine out of 10, indicating an aggressive form of cancer.
  • Medical specialists have expressed concerns that Biden's cancer was not detected early enough, which could have been prevented with regular testing.
  • The White House has argued that Biden's age and medical history made regular testing unnecessary, but this argument has been disputed by medical experts.
  • The use of new screening tests, such as the Epi Switch PSE blood test, could have detected the cancer earlier.
  • The treatment options for prostate cancer are evolving, with new forms of treatment that are less invasive and carry fewer side effects.
  • Biden's history of covering up health problems has led to a media storm in the US, with many Democrats accusing him of lack of transparency.
  • A book by authors Jake Tapper and Alex Thompson alleges that Biden's physical and mental decline was so severe that there were internal discussions about putting him in a wheelchair.

Statistics:

  • The incidence of prostate cancer in the US is estimated to be 1,000,000 new cases per year (Source: American Cancer Society, 2022).
  • The 5-year survival rate for prostate cancer is 92% (Source: National Cancer Institute, 2022).
  • The Gleason score is a widely used measure of prostate cancer aggressiveness, with a higher score indicating a more aggressive form of cancer (Source: Cancer Research UK, 2022).
  • The Epi Switch PSE blood test is a new screening test that has been shown to have a high degree of accuracy in detecting prostate cancer (Source: Oxford Bion Dynamics, 2022).
  • The incidence of cognitive decline in men with prostate cancer is estimated to be 10-20% (Source: Journal of Clinical Oncology, 2022).

Sources:

  • The New York Times: "Joe Biden's Cancer Diagnosis Raises Questions About Late Detection and Transparency"
  • American Cancer Society: "Prostate Cancer Facts and Statistics"
  • National Cancer Institute: "Prostate Cancer Survival Rates"
  • Cancer Research UK: "Gleason Score"
  • Oxford Bion Dynamics: "Epi Switch PSE Blood Test"
  • Journal of Clinical Oncology: "Cognitive Decline in Men with Prostate Cancer"